Bloomberg
BioNTech Chooses Singapore; Delhi Extends Lockdown: Virus Update
(Bloomberg) — BioNTech SE selected Singapore as its Southeast Asia headquarters and could have an operational Covid-19 vaccine production facility in the city by 2023.Earlier, Shanghai Fosun Pharmaceutical Group Co. said it will set up a joint venture with BioNTech, a sign that the highly effective inoculation is moving closer to getting approved for general use in China.The U.K. confirmed plans to allow indoor mixing from May 17, while the Czech Republic opened all shops, museums and galleries on Monday. India’s capital New Delhi extended its lockdown for another week amid a deadly wave of infections.Key DevelopmentsGlobal Tracker: Cases reach 158.3 million; deaths exceed 3.29 millionVaccine Tracker: More than 1.29 billion doses have been givenUnused shots pile up as mistrust blights Hong Kong vaccine drivePentagon presses on with Covid plan to speed cash to contractorsTokyo gives a taste of what Covid era Olympic games will be likeSubscribe to a daily update on the virus from Bloomberg’s Prognosis team here. Click CVID on the terminal for global data on cases and deaths.Norway Won’t Use Astra, J&J Vaccines (4:32 p.m. HK)A Norwegian expert committee recommended that AstraZeneca’s and Johnson & Johnson’s vaccines shouldn’t be included in the country’s inoculation program, but were open to making them available on a voluntary basis.The government last month ordered the committee to…
